Calibrant is pioneering the development of novel therapeutics using the Gemini™ discovery engine to elucidate disease pathways and protein networks from targeted cells captured from clinical tissue specimens.

Calibrant’s Gemini™ platform enables comprehensive and quantitative protein profiling of isolated and homogeneous cell populations from both fresh and archival formalin-fixed tissues, allowing us to approach the full biology of disease pathogenesis with exquisite sensitivity. With sample requirements uniquely matched to microdissection methods including laser capture microdissection (LCM), and coupled with an integrated bioinformatics suite enabling effective data mining within a biological context, Calibrant's approach provides unique benefits for drug discovery, drug development, and the identification of predictive markers for personalized medicine.

Get more information:

• About Calibrant >
• Biomarkers >
• Bioworld Today Feature